In light of these considerations, investigating the interplay between the CD155/TIGIT pathway and the metabolic behavior of CD8 + T cells in the context of TNBC holds promise for enhancing our understanding of tumor immune evasion and identifying potential therapeutic targets. This evidence concerns the gene CD8A and neoplasm.